Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06727552 · ClinicalTrials.gov registry record · Phase 2
A Study of Barzolvolimab in Patients With Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Celldex Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 20
- Study locations
NCT06727552: Active Phase 2 study of Atopic Dermatitis, sponsored by Celldex Therapeutics.
NCT06727552 is a Phase 2 study of Atopic Dermatitis that is active but no longer recruiting, run by Celldex Therapeutics. The registered enrollment target is 131 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06727552, a Phase 2 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Celldex Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis
Primary Outcome
Evaluate the clinical efficacy of 2 dose levels (150 mg and 300 mg) of barzolvolimab, compared to placebo, in adult participants with moderate to severe atopic dermatitis (AD) using the PP-NRS. The PP-NRS ranges from 0 = "no itch" to 10 ="worst imaginable itch" for the worst intensity itch in the preceding 24-hr period.
Conditions Studied
Interventions
- DRUG Matching placebo
- BIOLOGICAL Barzolvolimab
Study Locations (20)
California
- Ohara Aivaz MD Dermatology - Beverly Hills
- Advanced Dermatology Center - Burbank - Burbank
- 310 Clinical Research - Inglewood
- Avance Trials - Laguna Niguel
- LA Universal Research Center, Inc. - Los Angeles
- UCLA Division of Dermatology - Los Angeles
- Dynasty Dermatology - Pasadena
- Acclaim Clinical Research - San Diego
- Clinical Science Institute - Santa Monica
- FOMAT Medical Research - Allergy, Asthma, & Immunology Medical Group - Ventura
- Pacific Clinical Innovations Inc. - Vista
- Focus Clinical Research - West Hills
Florida
- Direct Helpers Research Center - Hialeah
- University of Miami - Miami
- International Dermatology Research Inc - Miami - Miami Lakes
- Sarasota Clinical Research - Sarasota
- Well Pharma Medical Research Corporation - South Miami
Alabama
- AllerVie Clinical Research - Birmingham
- Cahaba Dermatology & Skin Health Center, LLC - Birmingham
Georgia
- Centricity Research Columbus Dermatology - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What the registry record for NCT06727552 still lists
NCT06727552 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Matching placebo is the first listed.
NCT06727552 names 20 study sites across 4 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06727552 about?
NCT06727552 is a clinical study titled "A Study of Barzolvolimab in Patients With Atopic Dermatitis". The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis
What is the current status of trial NCT06727552?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2024-12-18. Estimated completion is 2027-05.
What conditions does trial NCT06727552 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06727552?
The interventions under investigation include: Matching placebo (DRUG), Barzolvolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06727552?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06727552 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06727552's enrollment target sits among peer trials
131 77th of 150 higher than 74 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI